PolyPid Ltd.

NasdaqCM PYPD

PolyPid Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2023: 1,404,368

PolyPid Ltd. Shares (Diluted, Weighted) is 1,404,368 for the year ending December 31, 2023, a 116.87% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

PolyPid Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 647,556, a 3.77% change year over year.
PolyPid Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 624,050, a 95.37% change year over year.
PolyPid Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 319,413, a -27.93% change year over year.
PolyPid Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 443,215, a 0.00% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: PYPD

PolyPid Ltd.

CEO	Ms. Dikla Czaczkes Akselbrad
IPO Date	June 26, 2020
Location	Israel
Headquarters	18 Hasivim Street
Employees	59
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Key trends

Past 5 years